Skip to main content
Exclusive Savings: Take 10% OFF All Cenmed Products | Upgrade Your Lab For Less Shop Now
US English

Aladdin Scientific

Acetazolamide sodium (C007B-325290)

Acetazolamide sodium is a carbonic anhydrase ( CA ) IX inhibitor with an IC 50 of 30 nM for hCA IX . Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.In VitroAcetazolamide also inhibits hCA II with an IC 50 of 130

Description
Acetazolamide sodium is a carbonic anhydrase ( CA ) IX inhibitor with an IC 50 of 30 nM for hCA IX . Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities.In VitroAcetazolamide also inhibits hCA II with an IC 50 of 130 nM. Acetazolamide (Ace) is a small heteroaromatic sulfonamide that binds to various carbonic anhydrases with high affinity, acting as a carbonic anhydrase (CA) inhibitor. Compared with the control group, the high Acetazolamide concentration (AceH, 50 nM), Cisplatin (Cis; 1 µg/mL) and Cis combined with the low Acetazolamide concentration (AceL, 10 nM) treatments significantly reduces viability of Hep-2 cells. Treatment with the Acetazolamide/Cis combination significantly increases the expression levels of P53, as both AceL+Cis and AceH+Cis treatments result in significantly increased P53 protein expression levels compared with the control group. The Ace/Cis combination treatment significantly reduces the bcl-2/bax expression ratio, and increases the expression of caspase-3 protein, compared with the control group. AceL, AceH, Cis and AceL+Cis treatments significantly reduce the bcl-2/bax ratio compared with the control group. Combined Ace and Cis treatment effectively promotes apoptosis in Hep-2 cells. Combined treatment with Ace/Cis markedly decreases the expression of AQP1 mRNA in Hep-2 cells. Both AceH and AceL+Cis treatments decrease the expression of aquaporin-1 (AQP1) mRNA in Hep-2 cells compared with the control group. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoAcetazolamide (40 mg/kg) significantly potentiates the inhibitory effect of MS-275 on tumorigenesis in neuroblastoma (NB) SH-SY5Y xenografts. Acetazolamide (40 mg/kg) and/or MS-275 treatment reduce expression of HIF1-α and CAIX in NB SH-SY5Y xenograft. Acetazolamide (40 mg/kg), MS-275 and Acetazolamide+MS-275 reduce expression of mitotic and proliferative markers in NB SH-SY5Y xenografts./nAcetazolamide (50 mg/kg; PO, for 3 days) significantly reduces the gonococcal load in the vagina of infected mice by 90% . MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:SolidIC50& Target:IC 50 : 30 nM (hCA IX), 130 nM (hCA II). Specification: 0.99 Molecular Formula: C4H6N4NaO3S2 Molecular Weight: 245.24 PubChem CID: 13290219 Isomeric SMILES: CC(=O)NC1=NN=C(S1)S(=O)(=O)[NH-].[Na+]
Specifications
UPC:
51141587
Condition:
New
Weight:
1.09 Ounces
HazmatClass:
No
Quantity:
1
Unit of Measurement:
EA
WeightUOM:
LB
MPN:
A648531-1g
CAS:
1424-27-7
Product Size:
1g
Catalog No. C007B-325290
Price: $174.63
List Price: $194.04
  • Guaranteed quality & reliable delivery
  • Shipping Lead-Time: 8-12 weeks
Adding to cart… The item has been added
Request a Quote

Enjoy exclusive benefits, including discounted pricing on bulk orders, by opening a Cenmed Business Account. Learn More.